Management of premenstrual Disorders ACOG clinical practice guideline nº 7

To provide recommendations for the management of premenstrual syndrome and premenstrual dysphoric disorder, collectively referred to as premenstrual disorders, based on assessment of the evidence regarding the safety and efficacy of available treatment options. An overview of the epidemiology, pathophysiology, and diagnosis of premenstrual disorders also is included to provide readers with relevant background information and context for the clinical recommendations.

Compounded bioidentical menopausal hormone therapy ACOG clinical consensus nº 6

Many compounding pharmacies use the phrase "bioidentical hormone" as a marketing term to imply that these preparations are natural and, thus, safer and more effective than U.S. Food and Drug Administration (FDA)­approved menopausal medications that use bioidentical or synthetic hormones or both. However, evidence to support marketing claims of safety and effectiveness is lacking. Compounded bioidentical menopausal hormone therapy should not be prescribed routinely when FDA-approved formulations exist. Clinicians should counsel patients that FDA-approved menopausal hormone therapies are recommended for the management of menopausal symptoms over compounded bioidentical menopausal hormone therapy. If a patient requests the use of compounded bioidentical menopausal hormone therapy, clinicians should educate them on the lack of FDA approval of these preparations and their potential risks and benefits, including the risks specific to compounding. To truly understand the benefits and harms of compounded bioidentical menopausal hormone therapy, high quality placebo-controlled randomized controlled trials with long-term follow-up comparing custom-compounded products with FDA-approved menopausal hormone therapy are needed.

Manejo actual de la rotura prematura de membranas en embarazos pretérmino

The obstetrician and gynecologist must frequently face complicated situations in the practice of obstetrics, one of them is the rupture of the membranes in a preterm pregnancy. While the medical conduct is to preserve both maternal and fetal health, many times the decision may affect fetal health in order to preserve the maternal health. This occurs when the presence of an infection makes it impossible to maintain the normal course of pregnancy and complete gestational age. In many cases the complications that cause prematurity of the newborn will put mother's life at risk and we must therefore be prepared to minimize the consequences of our decision. In this article we review evidence-based management that the obstetriciangynecologist should consider when this situation occurs.

Frecuentemente, el ginecólogo obstetra debe enfrentar situaciones complicadas en la práctica de la obstetricia; una de ellas es la rotura de membranas en un embarazo pretérmino. Si bien la conducta médica que debe tomar está encaminada a preservar la salud tanto materna como fetal, muchas veces, la decisión puede afectar la salud fetal en aras de preservar la salud materna. Esto ocurre cuando la presencia de una infección hace imposible mantener el curso normal de la gestación y la edad gestacional no es de término. En muchos casos, las complicaciones que ocasionará la prematuridad del recién nacido pondrán en riesgo su vida y por lo tanto debemos estar preparados para minimizar las consecuencias de nuestra decisión. En el presente artículo revisamos el manejo basado en evidencias, que el ginecólogo obstetra debería considerar cuando ocurre esta situación.

The American College of Obstetricians and Gynecologists: Women's Health Care Physicians

Ofrece información sobre el Colegio, sus autoridades, estructura y servicios. Provee acceso a materiales para educación continua de sus miembros y para sus pacientes, a sus publicaciones oficiales, a una libreria virtual, una agenda de eventos y un directorio de profesionales. Algunos materiales están disponibles en español

American College of Obstetricians and Gynecologists

Obstetricia, ginecología, publicaciones, información para pacientes, ética en obstetricia y ginecología

Gynecologic Oncology Group (GOG)

It's a national organization dedicated to clinical research in the field of gynecologic cancer. GOG receives support from the National Cancer Institute (NCI) of the National Institutes for Health (NIH) and the American College of Obstetricians and Gynecologists (ACOG). GOG consists of gynecologic oncologists, medical oncologists, radiation oncologists, immunologists, and pathologists specialists. Today, GOG consists of over 60 nationally known \"parent\" institutions, medical schools, colleges and universities and more that 125 affiliated hospitals. Approximately 45 individual clinical trials are active at any one time within GOG for patients with a variety of gynecologic malignancies, including cancers that arise from the ovaries, uterus, cervix, vagina, and vulva.